Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684.

@article{Hillner1997EconomicAO,
  title={Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684.},
  author={Bruce E. Hillner and John Munn Kirkwood and Michael B. Atkins and Edward R. Johnson and Thomas James Smith},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1997},
  volume={15 6},
  pages={2351-8}
}
PURPOSE Interferon alfa-2b (IFN) in a randomized clinical trial (E1684) prolonged relapse-free and total survival in high-risk resected melanoma. However, the costs and toxicities of IFN are barriers to its widespread use. This study was undertaken to analyze the projected costs and long-term benefits of IFN by combining prospectively collected data on IFN actual dosage, time of recurrence, and survival with secondary data on long-term melanoma recurrence risks to project the cost-effectiveness… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

Similar Papers

Loading similar papers…